                         SEQUENCE LISTING

<110>  H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
 
<120>  TIL ENHANCEMENT VIA EX VIVO STIMULATION WITH CD40 AGONISTS

<130>  10110-292WO1

<160>  4     

<170>  PatentIn version 3.5

<210>  1
<211>  336
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic construct

<400>  1
gatattgtga tgacccagtc tccactctct ctgtccgtcg cccctggaca gccggcctcc       60

atctcctgta agtctagtca gagcctcctg gagagttatg gagagaccta tttgtattgg      120

tacctgcaga agccaggcca gcctccacag ctcctgatct atgcagtttt taagcggttc      180

tctggagtgc cagataggtt cagtggcagc gggtcaggga cagatttcac actgaaaatc      240

agccgggtgg aggctgagga tgttggggtt tattactgca tgcaaagtat gcagcttcct      300

ctcactttcg gcggagggac caaggtggag atcaaa                                336


<210>  2
<211>  112
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic construct

<400>  2

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Ser Val Ala Pro Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Glu Ser 
            20                  25                  30          


Tyr Gly Glu Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Pro 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Ala Val Phe Lys Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ser 
                85                  90                  95      


Met Gln Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


<210>  3
<211>  366
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic construct

<400>  3
caggtgcagc tgcaggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc       60

tcctgtgcag cctctggatt caccttcaat aactttggca tacactgggt ccgccaggct      120

ccaggcaagg ggctggagtg ggtggcagtt atatcatatg atggaagtga taaatattat      180

gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgaat      240

ctgcaaatga atagtctgag agctgaggac acggctgtgt attactgtgc gagagatcgt      300

cggtattact accactacta cggtatggac gtctggggcc aagggaccat ggtcaccgtc      360

tcctca                                                                 366


<210>  4
<211>  122
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic construct

<400>  4

Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Asn Phe 
            20                  25                  30          


Gly Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Ser Tyr Asp Gly Ser Asp Lys Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Asn 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Arg Arg Tyr Tyr Tyr His Tyr Tyr Gly Met Asp Val Trp 
            100                 105                 110         


Gly Gln Gly Thr Met Val Thr Val Ser Ser 
        115                 120         


